CompletedPhase 4ACTRN12607000482460

The effect of bronchodilators on lung ventilation in chronic obstructive pulmonary disease

The effect of tiotropium bromide on ventilation perfusion heterogeneity in chronic obstructive pulmonary disease


Sponsor

The Woolcock Institute of Medical Research

Enrollment

15 participants

Start Date

Aug 4, 2007

Study Type

Interventional

Conditions

Summary

Chronic Obstructive Pulmonary Disease (COPD) is a common disorder which causes changes within the airways and blood vessels of the lung. As a result of these changes, it can cause problems with breathing and the way air and oxygen travels to different parts of the lung. We have several different ways of looking at how bad COPD is, however none of these are perfect. By understanding better the way in which airways behave in COPD, and the effects this has on blood flow within the lung, the better able we will be to investigate, develop new medications, and treat COPD. In this study we will be investigating the way COPD affects breathing and blood flow by looking at changes in lung function. We will then compare this information with pictures of breathing and blood flow obtained from a nuclear medicine scan.


Eligibility

Sex: Both males and femalesMin Age: 40 Yearss

Plain Language Summary

Simplified for easier understanding

This study looks at the effect of bronchodilators on lung ventilation in chronic obstructive pulmonary disease. It is open to both men and women aged 40 Years and older. Participants will be screened based on specific health criteria to see if they qualify. If you join, the research team will explain what is involved and monitor your health throughout the study.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Washout period is one week between interventions. Single dose of 18µg tiotropium bromide and 200µg salbutamol. Both drugs are inhaled

Washout period is one week between interventions. Single dose of 18µg tiotropium bromide and 200µg salbutamol. Both drugs are inhaled


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12607000482460


Related Trials